Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;45(2):71-4.
doi: 10.1053/j.seminhematol.2008.02.005.

Monoclonal antibodies in lymphoma: the first decade

Brian K Link  1 , Jonathan W Friedberg
Affiliations

Monoclonal antibodies in lymphoma: the first decade

Brian K Link et al. Semin Hematol. 2008 Apr.

Abstract

The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has significantly contributed to these improved therapeutic outcomes. This issue will explore the impact of monoclonal antibody therapy on outcome in indolent lymphoma, and detail how this improved outcome has changed clinical practice. Furthermore, the role of monoclonal antibodies in maintenance regimens and the main indications for radiolabeled antibodies will be discussed in detail. Finally, possible future developments in the field will be proposed, including the use of monoclonal antibodies in ablative transplantation and in the treatment of leukemias.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BKl. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026. - PubMed
    1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TPl. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452. - PubMed
    1. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582–1589. - PubMed
    1. Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007;109:2077–2082. - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732. - PubMed

Publication types

MeSH terms